{"id":5775,"date":"2024-09-12T15:05:02","date_gmt":"2024-09-12T20:05:02","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5775"},"modified":"2025-06-27T11:13:06","modified_gmt":"2025-06-27T16:13:06","slug":"nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/","title":{"rendered":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0646 \u0627\u062c\u062a\u0645\u0627\u0639 \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0639 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0648\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621 \u062a\u062c\u0631\u0628\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0644\u0640 MCO-010 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u064a Stargardt"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5775\" class=\"elementor elementor-5775\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-1b9d610d elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1b9d610d\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fb9e512\" data-id=\"fb9e512\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7f871d16 elementor-widget elementor-widget-text-editor\" data-id=\"7f871d16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><em><strong>\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u0646 \u062a\u0628\u062f\u0623 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0633\u062c\u064a\u0644 \u0641\u064a \u0648\u0642\u062a \u0642\u0631\u064a\u0628.<\/strong><\/em><\/p><p>\u062f\u0627\u0644\u0627\u0633\u060c,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">12 \u0633\u0628\u062a\u0645\u0628\u0631 2024<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ar\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0644\u0644\u0639\u0644\u0627\u062c\u0627\u062a<\/a>\u0623\u0639\u0644\u0646\u062a \u0627\u0644\u064a\u0648\u0645 \u0634\u0631\u0643\u0629 \u0633\u064a\u0633\u062a\u0645\u0632\u060c \u0648\u0647\u064a \u0634\u0631\u0643\u0629 \u0644\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0641\u064a \u0645\u0631\u062d\u0644\u0629 \u0645\u062a\u0623\u062e\u0631\u0629 \u062a\u0639\u0645\u0644 \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a \u0648\u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a \u0627\u0644\u0645\u0631\u062a\u0628\u0637 \u0628\u0627\u0644\u0639\u0645\u0631 (AMD)\u060c \u0639\u0646 \u0627\u062c\u062a\u0645\u0627\u0639 \u0645\u062b\u0645\u0631 \u0641\u064a \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 (EOP2) \u0645\u0639 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0644\u0628\u0631\u0646\u0627\u0645\u062c\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0631\u064a \u0644\u062a\u0642\u064a\u064a\u0645 MCO-010 \u0644\u0639\u0644\u0627\u062c \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0634\u062f\u064a\u062f \u0628\u0633\u0628\u0628 \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SMD)\u060c \u0648\u062f\u0639\u0645 \u062a\u0642\u062f\u0645 MCO-010 \u0625\u0644\u0649 \u062a\u062c\u0631\u0628\u0629 \u062a\u0633\u062c\u064a\u0644\u064a\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629.<\/p><p>\u0648\u062a\u0636\u0645\u0646\u062a \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629 \u0644\u0645\u0646\u0627\u0642\u0634\u0629 \u0627\u062c\u062a\u0645\u0627\u0639 EOP2 \u0645\u0627 \u064a\u0644\u064a:<\/p><ul type=\"disc\"><li>\u0642\u062f\u0645\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0645\u062f\u062e\u0644\u0627\u062a \u0648\u0627\u0636\u062d\u0629 \u0628\u0634\u0623\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u062a\u0633\u062c\u064a\u0644\u064a\u0629 \u0627\u0644\u0645\u0642\u062a\u0631\u062d\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0627\u0639\u062a\u0644\u0627\u0644 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0633\u0643\u0631\u064a \u0628\u0647\u062f\u0641 \u062f\u0639\u0645 \u0633\u0644\u0627\u0645\u0629 \u0648\u0641\u0639\u0627\u0644\u064a\u0629 MCO-010. \u0633\u064a\u062a\u0643\u0648\u0646 \u062a\u0635\u0645\u064a\u0645 \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u0642\u062a\u0631\u062d\u0629 \u0645\u0646 \u0645\u062c\u0645\u0648\u0639\u0629 \u062c\u0631\u0639\u0629 \u0648\u0627\u062d\u062f\u0629 \u0645\u0646 MCO-010 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a\u060c \u064a\u062a\u0645 \u062a\u0648\u0632\u064a\u0639\u0647\u0627 \u0639\u0634\u0648\u0627\u0626\u064a\u064b\u0627 \u0628\u0646\u0633\u0628\u0629 1:1 \u0639\u0644\u0649 \u0645\u062c\u0645\u0648\u0639\u0629 \u062a\u062d\u0643\u0645 \u062a\u062a\u0644\u0642\u0649 \u062d\u0642\u0646\u0629 \u0648\u0647\u0645\u064a\u0629.<\/li><li>\u0623\u0643\u062f\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0623\u0646 \u0627\u0644\u062a\u063a\u064a\u064a\u0631 \u0641\u064a \u0623\u0641\u0636\u0644 \u062d\u062f\u0629 \u0628\u0635\u0631\u064a\u0629 \u0645\u0635\u062d\u062d\u0629 (BCVA) \u0627\u0644\u0630\u064a \u064a\u0633\u062a\u062e\u062f\u0645 \u0627\u0644\u0627\u062e\u062a\u0628\u0627\u0631 \u0639\u0644\u0649 \u0645\u062e\u0637\u0637 ETDRS \u0645\u0646\u0627\u0633\u0628 \u0644\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0641\u064a \u0646\u0642\u0637\u0629 \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u0629 \u0644\u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u062a\u063a\u064a\u064a\u0631 \u0645\u0646 \u0627\u0644\u0623\u0633\u0627\u0633 \u0625\u0644\u0649 \u0627\u0644\u0623\u0633\u0628\u0648\u0639 52 \u0641\u064a \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0645\u0642\u062a\u0631\u062d\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 3.<\/li><li>\u0642\u062f\u0645\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0645\u062f\u062e\u0644\u0627\u062a \u0642\u064a\u0645\u0629 \u062d\u0648\u0644 \u0627\u0644\u0623\u0633\u0627\u0644\u064a\u0628 \u0627\u0644\u0625\u062d\u0635\u0627\u0626\u064a\u0629 \u0644\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0648\u0627\u0644\u062b\u0627\u0646\u0648\u064a\u0629 \u0627\u0644\u0645\u0642\u062a\u0631\u062d\u0629 \u0648\u0627\u0644\u062a\u064a \u0633\u062a\u0633\u0627\u0647\u0645 \u0641\u064a \u0645\u0632\u064a\u062f \u0645\u0646 \u0627\u0644\u062a\u0639\u0627\u0648\u0646 \u0645\u0639 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0644\u0644\u062a\u0648\u0627\u0641\u0642 \u0645\u0639 \u0627\u0644\u062a\u062d\u0644\u064a\u0644\u0627\u062a \u0627\u0644\u0625\u062d\u0635\u0627\u0626\u064a\u0629.<\/li><li>\u0648\u0639\u0631\u0636\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0645\u0648\u0627\u0635\u0644\u0629 \u0627\u0644\u0645\u0646\u0627\u0642\u0634\u0629 \u0648\u0627\u0644\u0645\u0633\u0627\u0639\u062f\u0629 \u0641\u064a \u0627\u0644\u062a\u062e\u0637\u064a\u0637 \u0644\u0645\u0632\u064a\u062f \u0645\u0646 \u0627\u0644\u062a\u0642\u064a\u064a\u0645 \u0644\u0627\u062e\u062a\u0628\u0627\u0631 \u0627\u0644\u062a\u0645\u064a\u064a\u0632 \u0628\u064a\u0646 \u0627\u0644\u0623\u0634\u0643\u0627\u0644 \u0627\u0644\u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0633\u0637\u0648\u0639 \u0644\u062f\u0639\u0645 \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0643\u0646\u0642\u0637\u0629 \u0646\u0647\u0627\u064a\u0629 \u062b\u0627\u0646\u0648\u064a\u0629 \u0631\u0626\u064a\u0633\u064a\u0629.<\/li><li>\u062a\u0645 \u062a\u062d\u0642\u064a\u0642 \u0627\u0644\u062a\u0648\u0627\u0641\u0642 \u0639\u0646\u062f \u062a\u0633\u062c\u064a\u0644 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0643\u0641\u0648\u0641\u064a\u0646 \u0642\u0627\u0646\u0648\u0646\u064a\u064b\u0627 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0623\u0633\u0648\u0623 \u0645\u0646 20\/200\u060c \u0648\u0627\u0644\u0630\u064a\u0646 \u062a\u0635\u0644 \u0623\u0639\u0645\u0627\u0631\u0647\u0645 \u0625\u0644\u0649 12 \u0639\u0627\u0645\u064b\u0627\u060c \u0644\u0644\u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0642\u0627\u062f\u0645\u0629\u060c \u0645\u0645\u0627 \u0623\u062f\u0649 \u0625\u0644\u0649 \u062a\u0648\u0633\u064a\u0639 \u0646\u0637\u0627\u0642 \u0627\u0644\u0633\u0643\u0627\u0646 \u0627\u0644\u0630\u064a\u0646 \u062a\u0645 \u062a\u0642\u064a\u064a\u0645\u0647\u0645 \u0645\u0646 \u0623\u0648\u0644\u0626\u0643 \u0627\u0644\u0630\u064a\u0646 \u062a\u0645\u062a \u062f\u0631\u0627\u0633\u062a\u0647\u0645 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629.<\/li><li>\u0648\u0627\u0641\u0642\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0639\u0644\u0649 \u0643\u0641\u0627\u064a\u0629 \u0627\u0644\u062d\u0632\u0645\u0629 \u063a\u064a\u0631 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u062d\u0627\u0644\u064a\u0629 \u0644\u062f\u0639\u0645 \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u0628\u064a\u0648\u0644\u0648\u062c\u064a \u0628\u064a\u0648\u0644\u0648\u062c\u064a \u0645\u0633\u062a\u0642\u0628\u0644\u064a.<\/li><\/ul><p>\u201c&quot;\u064a\u0648\u0627\u062c\u0647 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a \u0639\u0628\u0626\u064b\u0627 \u0645\u0631\u0636\u064a\u064b\u0627 \u0643\u0628\u064a\u0631\u064b\u0627 \u0641\u064a \u0638\u0644 \u0639\u062f\u0645 \u062a\u0648\u0641\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u062a\u0631\u0645\u064a\u0645\u064a\u0629 \u0641\u064a \u0627\u0644\u0648\u0642\u062a \u0627\u0644\u062d\u0627\u0644\u064a&quot;\u060c\u00a0<span class=\"xn-person\">\u0633\u0648\u0644\u0627\u062c\u0646\u0627 \u0628\u0647\u0627\u062a\u0627\u0634\u0627\u0631\u064a\u0627<\/span>, \u060c \u0627\u0644\u0645\u0624\u0633\u0633 \u0627\u0644\u0645\u0634\u0627\u0631\u0643 \u0648\u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628. &quot;\u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT\u060c \u062a\u0639\u0632\u0632 \u0646\u062a\u0627\u0626\u062c \u0647\u0630\u0627 \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0642\u0646\u0627\u0639\u062a\u0646\u0627 \u0628\u0636\u0631\u0648\u0631\u0629 \u0627\u0644\u0645\u0636\u064a \u0642\u062f\u0645\u064b\u0627 \u0641\u064a \u062a\u0637\u0648\u064a\u0631 MCO-010 \u0633\u0631\u064a\u0631\u064a\u064b\u0627 \u0644\u0647\u0630\u0627 \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645. \u0648\u0646\u062d\u0646 \u0646\u0642\u062f\u0631 \u062a\u0648\u062c\u064a\u0647\u0627\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0648\u0646\u062a\u0637\u0644\u0639 \u0625\u0644\u0649 \u0627\u0633\u062a\u0643\u0645\u0627\u0644 \u0627\u0644\u0627\u0633\u062a\u0639\u062f\u0627\u062f\u0627\u062a \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629.&quot;\u201c<\/p><p>\u201c&quot;\u0625\u0646 \u0627\u0644\u0646\u0645\u0648\u0630\u062c \u0627\u0644\u062d\u0627\u0644\u064a \u0644\u0625\u062f\u0627\u0631\u0629 \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a \u064a\u0642\u0648\u0645 \u0639\u0644\u0649 \u0627\u0644\u062a\u0634\u062e\u064a\u0635\u060c \u064a\u0644\u064a\u0647 \u0625\u0639\u0627\u062f\u0629 \u062a\u0623\u0647\u064a\u0644 \u0627\u0644\u0628\u0635\u0631\u060c \u062b\u0645 \u062d\u0643\u0645 \u0645\u062f\u0649 \u0627\u0644\u062d\u064a\u0627\u0629 \u0628\u062a\u062f\u0647\u0648\u0631 \u0627\u0644\u0628\u0635\u0631 \u0648\u0635\u0648\u0644\u0627\u064b \u0625\u0644\u0649 \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u0634\u062f\u064a\u062f. \u0625\u0646 \u062a\u0642\u062f\u0645 \u0639\u0644\u0627\u062c \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0627\u0644\u0631\u0627\u0626\u062f \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a \u0625\u0644\u0649 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0633\u062c\u064a\u0644 \u064a\u0642\u0631\u0628\u0646\u0627 \u0643\u062b\u064a\u0631\u0627\u064b \u0645\u0646 \u0627\u0644\u062d\u0635\u0648\u0644 \u0639\u0644\u0649 \u062e\u064a\u0627\u0631 \u0639\u0644\u0627\u062c\u064a \u0641\u0639\u0627\u0644 \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0647\u0630\u0627 \u0627\u0644\u0645\u0631\u0636 \u0627\u0644\u062e\u0637\u064a\u0631&quot;.\u00a0<span class=\"xn-person\">\u0635\u0645\u0648\u0626\u064a\u0644 \u0628\u0627\u0631\u0648\u0646<\/span>\u062f\u0643\u062a\u0648\u0631 \u0641\u064a \u0627\u0644\u0637\u0628\u060c \u0643\u0628\u064a\u0631 \u0627\u0644\u0645\u0633\u0624\u0648\u0644\u064a\u0646 \u0627\u0644\u0637\u0628\u064a\u064a\u0646.<\/p><p>\u0633\u062a\u0643\u0648\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0645\u062e\u0637\u0637 \u0644\u0647\u0627 \u0623\u0648\u0644 \u062a\u062c\u0631\u0628\u0629 \u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0645\u0636\u0628\u0648\u0637\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a. \u064a\u062a\u0645\u062a\u0639 \u0627\u0644\u0646\u0647\u062c \u0627\u0644\u0639\u0644\u0627\u062c\u064a \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628\u060c \u0627\u0644\u0630\u064a \u0644\u0627 \u064a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u0637\u0641\u0631\u0627\u062a \u0627\u0644\u062c\u064a\u0646\u064a\u0629\u060c \u0628\u0625\u0645\u0643\u0627\u0646\u064a\u0629 \u062a\u062d\u0633\u064a\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0644\u062f\u0649 \u0627\u0644\u0639\u062f\u064a\u062f \u0645\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631\u060c \u0628\u0645\u0646 \u0641\u064a\u0647\u0645 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a.<\/p><p><b>\u062d\u0648\u0644 \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a<br class=\"dnr\" \/><\/b>\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a\u060c \u0648\u0627\u0644\u0630\u064a \u064a\u064f\u0637\u0644\u0642 \u0639\u0644\u064a\u0647 \u063a\u0627\u0644\u0628\u064b\u0627 \u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621 \u0639\u0646\u062f \u0627\u0644\u0623\u0637\u0641\u0627\u0644\u060c \u0647\u0648 \u0645\u0631\u0636 \u064a\u0635\u064a\u0628 \u0627\u0644\u0639\u064a\u0646 \u0648\u064a\u0638\u0647\u0631 \u0641\u064a \u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0637\u0641\u0648\u0644\u0629 \u0648\u0647\u0648 \u0627\u0644\u0633\u0628\u0628 \u0627\u0644\u0631\u0626\u064a\u0633\u064a \u0644\u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0639\u0646\u062f \u0627\u0644\u0623\u0637\u0641\u0627\u0644 \u0648\u0627\u0644\u0634\u0628\u0627\u0628. \u0648\u0647\u0648 \u0645\u0631\u0636 \u0648\u0631\u0627\u062b\u064a\u060c \u0623\u064a \u0623\u0646\u0647 \u064a\u0646\u062a\u0642\u0644 \u0625\u0644\u0649 \u0627\u0644\u0623\u0637\u0641\u0627\u0644 \u0645\u0646 \u062e\u0644\u0627\u0644 \u062c\u064a\u0646\u0627\u062a \u0645\u0639\u064a\u0628\u0629 \u0645\u0646 \u0648\u0627\u0644\u062f\u064a\u0647\u0645. \u0641\u064a \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a\u060c \u062a\u062a\u062f\u0647\u0648\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621 \u0641\u064a \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621 \u0645\u0645\u0627 \u064a\u0624\u062f\u064a \u0625\u0644\u0649 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0645\u0631\u0643\u0632\u064a\u0629. \u062d\u0627\u0644\u064a\u064b\u0627\u060c \u0644\u0627 \u062a\u0648\u062c\u062f \u0639\u0644\u0627\u062c\u0627\u062a \u0645\u0639\u062a\u0645\u062f\u0629.<\/p><p><b>\u062d\u0648\u0644 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u064a\u0643\u0633 \u0625\u0646\u0643.<br class=\"dnr\" \/><\/b>\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0628\u0635\u0631\u064a\u0629 \u0648\u0631\u0627\u062b\u064a\u0629 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0644\u0627 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u062c\u064a\u0646\u0627\u062a\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u0644\u0627 \u064a\u0648\u062c\u062f \u0644\u0647\u0627 \u0639\u0644\u0627\u062c. \u0648\u0642\u062f \u0623\u0639\u0644\u0646\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0645\u0624\u062e\u0631\u0627\u064b \u0639\u0646 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0644\u0645\u0646\u062a\u062c\u0647\u0627 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u060c MCO-010\u060c \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 RESTORE\u060c \u0648\u0647\u064a \u062a\u062c\u0631\u0628\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0645\u0636\u0628\u0648\u0637\u0629 \u0628\u0627\u0644\u063a\u0641\u0644\u060c \u0623\u062c\u0631\u064a\u062a \u0641\u064a \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP).<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4253597-1&h=3186461145&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3939588-1%26h%3D1414634841%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3823946-1%2526h%253D153867349%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT04945772%25253Fterm%25253DNanoscope%252526draw%25253D2%2526a%253DNCT04945772%26a%3DNCT04945772&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). \u0643\u0645\u0627 \u0623\u0643\u0645\u0644\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u062a\u062c\u0631\u0628\u0629 STARLIGHT \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 MCO-010 \u0641\u064a \u0645\u0631\u0636\u0649 \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4253597-1&h=3896378782&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3939588-1%26h%3D1223114861%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT05417126%26a%3DNCT05417126&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>). \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0648\u062a\u0635\u0646\u064a\u0641 \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0644\u0643\u0644 \u0645\u0646 RP \u0648\u0645\u0631\u0636 Stargardt. \u062a\u0634\u0645\u0644 \u0627\u0644\u0623\u0635\u0648\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0633\u0627\u0628\u0642\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a MCO-020 \u0627\u0644\u0630\u064a \u064a\u062a\u0645 \u062a\u0648\u0635\u064a\u0644\u0647 \u0628\u0627\u0644\u0644\u064a\u0632\u0631 \u063a\u064a\u0631 \u0627\u0644\u0641\u064a\u0631\u0648\u0633\u064a \u0644\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a.<\/p><p><b>\u0627\u0644\u0627\u062a\u0635\u0627\u0644 \u0628\u0627\u0644\u0645\u0633\u062a\u062b\u0645\u0631:<\/b><br class=\"dnr\" \/>\u0634\u0631\u0643\u0627\u0621 \u0623\u0631\u063a\u0648\u062a<br class=\"dnr\" \/>(212) 600-1902<br class=\"dnr\" \/><a href=\"mailto:pr@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">pr@nanostherapeutics.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Phase 3 Registrational Trial Expected to Commence in Near-term DALLAS,\u00a0Sept. 12, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases and age-related macular degeneration (AMD), today announced a productive End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5777,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-12T20:05:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:13:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration\",\"datePublished\":\"2024-09-12T20:05:02+00:00\",\"dateModified\":\"2025-06-27T16:13:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/\"},\"wordCount\":657,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_STARGARDTV3.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/\",\"name\":\"Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_STARGARDTV3.jpg\",\"datePublished\":\"2024-09-12T20:05:02+00:00\",\"dateModified\":\"2025-06-27T16:13:06+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_STARGARDTV3.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_STARGARDTV3.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/12\\\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0627\u062c\u062a\u0645\u0627\u0639\u0647\u0627 \u0645\u0639 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0641\u064a \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629\u060c \u0648\u0639\u0646 \u062e\u0637\u062a\u0647\u0627 \u0644\u0628\u062f\u0621 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0639\u0642\u0627\u0631 MCO-010 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a.","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-09-12T20:05:02+00:00","article_modified_time":"2025-06-27T16:13:06+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Nanoscope Therapeutics","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"3 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration","datePublished":"2024-09-12T20:05:02+00:00","dateModified":"2025-06-27T16:13:06+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/"},"wordCount":657,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/","url":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/","name":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0627\u062c\u062a\u0645\u0627\u0639\u0647\u0627 \u0645\u0639 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0641\u064a \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629\u060c \u0648\u0639\u0646 \u062e\u0637\u062a\u0647\u0627 \u0644\u0628\u062f\u0621 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0639\u0642\u0627\u0631 MCO-010 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","datePublished":"2024-09-12T20:05:02+00:00","dateModified":"2025-06-27T16:13:06+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/5775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=5775"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/5775\/revisions"}],"predecessor-version":[{"id":9039,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/5775\/revisions\/9039"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/5777"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=5775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=5775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=5775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}